Actelion Company Profile (OTCMKTS:ALIOF)

About Actelion

Actelion Ltd is a Switzerland-based biopharmaceutical company that focuses on the discovery, development and commercialization of drugs for diseases with unmet medical needs. The Company specializes in the field of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs. Its portfolio of PAH treatments includes Opsumit (macitentan), Tracleer (bosentan), Uptravi (selexipag), Veletri (epoprostenol for injection) and Ventavis (iloprost). Opsumit is an orally available endothelin receptor antagonist (ERA). Tracleer is an orally available endothelin receptor antagonist (ERA). Uptravi is an oral, selective IP receptor agonist targeting the prostacyclin pathway in PAH. Veletri (epoprostenol for injection) is an intravenous prostacyclin. Ventavis is an inhaled formulation of iloprost, a synthetic compound similar to prostacyclin (PGI2).

Industry, Sector and Symbol:

Sector: Medical
Industry: N/A
Sub-Industry: N/A
Exchange: OTCMKTS
Symbol: ALIOF
CUSIP:

Key Metrics:

Previous Close: $172.60
50 Day Moving Average: $169.18
200 Day Moving Average: $162.47
52-Week Range: $122.00 - $175.71
Trailing P/E Ratio: 29.54
Foreward P/E Ratio: 21.58
P/E Growth: 0.00
Market Cap: $18.15B
Outstanding Shares: 105,185,000
Beta: 1.32

Profitability:

Net Margins: 27.07%
Return on Equity: 47.08%
Return on Assets: 30.95%

Debt:

Current Ratio: 2.56%
Quick Ratio: 2.32%

Additional Links:

Companies Related to Actelion:

Consensus Ratings for Actelion (OTCMKTS:ALIOF) (?)

Ratings Breakdown:	No ratings tracked in the last 12 months.
Consensus Rating:	N/A (Score: NaN)
Consensus Price Target:	N/A

Analysts' Ratings History for Actelion (OTCMKTS:ALIOF)

Show:

Date	Firm	Action	Rating	Price Target	Details
6/25/2015	HSBC	Initiated Coverage	Hold

(Data available from 9/29/2014 forward)

Earnings History for Actelion (OTCMKTS:ALIOF)

Date	Consensus Estimate	Actual EPS	Release Link	Conference Call
10/20/2015	$1.61	$1.90	View	N/A
4/21/2015	$1.28	$1.68	View	N/A
2/16/2015	$1.13	$0.81	View	N/A
10/21/2014	$1.50	$1.61	View	N/A
7/23/2014	$1.37	$2.00	View	N/A
4/21/2014	$1.12	$1.65	View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Actelion (OTCMKTS:ALIOF)

Current Year EPS Consensus Estimate: $8.36 EPS
Next Year EPS Consensus Estimate: $8 EPS

Dividend History for Actelion (OTCMKTS:ALIOF)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Actelion (OTCMKTS:ALIOF)
No insider trades for this company have been tracked by MarketBeat.com

Latest Headlines for Actelion (OTCMKTS:ALIOF)

Date	Headline
	Actelion to investigate all-oral combination therapy for patients with relapsing multiple sclerosis (OTCMKTS:ALIOF) www.publicnow.com - September 29 at 8:12 AM
	Actelion Ltd. – Value Analysis (US OTC:ALIOF) : September 21, 2016 (OTCMKTS:ALIOF) www.capitalcube.com - September 21 at 4:20 PM
	Actelion Ltd. breached its 50 day moving average in a Bullish Manner : ALIOF-US : September 20, 2016 (OTCMKTS:ALIOF) www.capitalcube.com - September 20 at 9:15 AM
	Dynavax Rebounds on Same PDUFA Date for Heplisav BLA (OTCMKTS:ALIOF) finance.yahoo.com - September 7 at 12:23 PM
	Why Actelion (ALIOF) Isn't Done Growing Earnings Yet (OTCMKTS:ALIOF) www.zacks.com - September 2 at 8:04 AM
	Pfizer's Lung Cancer Drug Xalkori Label Expanded in the EU (OTCMKTS:ALIOF) finance.yahoo.com - September 1 at 11:57 AM
	Array (ARRY) Presents Positive Cardiovascular Trial Data (OTCMKTS:ALIOF) finance.yahoo.com - August 31 at 3:29 PM
	Amgen Gets CRL for Secondary Hyperparathyroidism Drug (OTCMKTS:ALIOF) finance.yahoo.com - August 25 at 3:28 PM
	Pfizer to Acquire Rights to AstraZeneca's Antibiotics Business (OTCMKTS:ALIOF) finance.yahoo.com - August 24 at 11:43 AM
	Galapagos (GLPG) Advances RA Drug Filgotinib to Phase III (OTCMKTS:ALIOF) finance.yahoo.com - August 23 at 3:26 PM
	ETF’s with exposure to Actelion Ltd. : August 23, 2016 (OTCMKTS:ALIOF) www.capitalcube.com - August 23 at 3:26 PM
	Pfizer to Buy Medivation for $14B, Boost Cancer Franchise (revised) (OTCMKTS:ALIOF) finance.yahoo.com - August 23 at 8:26 AM
	Pfizer-Medivation Close to Signing $14B Acquisition Deal? (revised) (OTCMKTS:ALIOF) finance.yahoo.com - August 22 at 8:35 PM
	Actelion completes first-line share purchase program (OTCMKTS:ALIOF) www.publicnow.com - August 22 at 8:13 AM
	Pfizer-Medivation Close to Signing $14B Acquisition Deal? (OTCMKTS:ALIOF) finance.yahoo.com - August 22 at 8:13 AM
	Intercept (ICPT) Ocaliva Phase III POISE Data Published (OTCMKTS:ALIOF) finance.yahoo.com - August 18 at 11:49 AM
	Cytokinetics' Amyotrophic Lateral Sclerosis Study Enrolled (OTCMKTS:ALIOF) finance.yahoo.com - August 18 at 11:49 AM
	Actelion (ALIOF) Uptravi Approved for PAH in Switzerland (OTCMKTS:ALIOF) finance.yahoo.com - August 17 at 11:39 AM
	Glaxo/Pfizer ViiV Healthcare Starts HIV Drug Combo Study (OTCMKTS:ALIOF) finance.yahoo.com - August 17 at 11:39 AM
	Actelion : receives Swissmedic approval for Uptravi (selexipag) for treatment of pulmonary arterial hypertension (OTCMKTS:ALIOF) www.4-traders.com - August 16 at 8:44 PM
	Actelion receives Swissmedic approval for Uptravi (selexipag) for treatment of pulmonary arterial hypertension (OTCMKTS:ALIOF) www.publicnow.com - August 16 at 12:01 PM
	Is ACTELION (ALIOF) Stock a Solid Choice Right Now? (OTCMKTS:ALIOF) finance.yahoo.com - August 12 at 12:00 PM
	ETF’s with exposure to Actelion Ltd. : August 10, 2016 (OTCMKTS:ALIOF) www.capitalcube.com - August 10 at 3:47 PM
	Actelion Ltd. breached its 50 day moving average in a Bearish Manner : ALIOF-US : August 9, 2016 (OTCMKTS:ALIOF) www.capitalcube.com - August 9 at 12:11 PM
	Actelion Ltd. :ALIOF-US: Earnings Analysis: Q2, 2016 By the Numbers : August 2, 2016 (OTCMKTS:ALIOF) www.capitalcube.com - August 2 at 3:27 PM
	Why ACTELION (ALIOF) Could Be an Impressive Growth Stock (OTCMKTS:ALIOF) finance.yahoo.com - July 28 at 8:37 AM
	Actelion (ALIOF) Beats Q2 Earnings & Revenues, View Up (OTCMKTS:ALIOF) finance.yahoo.com - July 22 at 1:13 PM
	Actelion H1 Net Income Rises (OTCMKTS:ALIOF) potiner.com - July 21 at 9:00 PM
	Actelion H1 Net Income Rises - Quick Facts (OTCMKTS:ALIOF) www.nasdaq.com - July 21 at 9:00 PM
	ETF’s with exposure to Actelion Ltd. : July 19, 2016 (OTCMKTS:ALIOF) www.capitalcube.com - July 19 at 11:56 AM
	Actelion Ltd. :ALIOF-US: Earnings Analysis: Q1, 2016 By the Numbers : June 28, 2016 (OTCMKTS:ALIOF) www.capitalcube.com - June 28 at 11:14 AM
	Actelion Ltd. breached its 50 day moving average in a Bearish Manner : ALIOF-US : June 27, 2016 (OTCMKTS:ALIOF) www.capitalcube.com - June 27 at 11:12 AM
	Actelion Ltd. – Value Analysis (US OTC:ALIOF) : June 17, 2016 (OTCMKTS:ALIOF) www.capitalcube.com - June 17 at 11:50 AM
	Actelion Ltd. breached its 50 day moving average in a Bearish Manner : ALIOF-US : June 15, 2016 (OTCMKTS:ALIOF) www.capitalcube.com - June 15 at 8:09 AM
	ETF’s with exposure to Actelion Ltd. : April 22, 2016 (OTCMKTS:ALIOF) www.capitalcube.com - April 22 at 3:01 PM
	Actelion Ltd. :ALIOF-US: Earnings Analysis: Q1, 2016 By the Numbers (OTCMKTS:ALIOF) www.capitalcube.com - April 22 at 9:19 AM
	Clovis Hits 52-week Low Post Rociletinib Briefing Documents (OTCMKTS:ALIOF) finance.yahoo.com - April 11 at 3:45 PM
	Ionis Tanks, FDA Clinical Hold on IONIS-TTRRx Phase III Study (OTCMKTS:ALIOF) finance.yahoo.com - April 8 at 4:40 PM
	Intercept's (ICPT) Ocaliva Gets Favorable FDA Panel Vote (OTCMKTS:ALIOF) finance.yahoo.com - April 8 at 3:35 PM
	Illumina Unveils BaseSpace Suite, Boosts Precision Medicine (OTCMKTS:ALIOF) finance.yahoo.com - April 8 at 1:55 PM
	Ironwood Slumps, Halts Development of Gastroparesis Drug (OTCMKTS:ALIOF) finance.yahoo.com - April 6 at 10:10 AM
	AbbVie Up, Wins CHMP Backing for Humira's Expanded Use (OTCMKTS:ALIOF) finance.yahoo.com - April 5 at 11:20 AM
	Sarepta's Q4 Loss Wider than Expected, Eteplirsen in Focus (OTCMKTS:ALIOF) finance.yahoo.com - February 26 at 11:50 AM
	Keryx Posts Wider-than-Expected Loss in Q4, Auryxia Grows (OTCMKTS:ALIOF) finance.yahoo.com - February 26 at 9:50 AM
	Ionis Incurs Wider-than-Expected Loss in Q4, Shares Down (OTCMKTS:ALIOF) finance.yahoo.com - February 26 at 9:45 AM
	Geron Q4 Loss In-Line with Estimates, Imetelstat in Focus (OTCMKTS:ALIOF) finance.yahoo.com - February 26 at 9:35 AM
	Anika Therapeutics (ANIK) Jumps: Stock Moves Up 8% (OTCMKTS:ALIOF) finance.yahoo.com - February 26 at 8:15 AM
	Actelion Profit Jumps, Proposes Higher Dividend; Sees Growth In FY16 Core Income (OTCMKTS:ALIOF) www.nasdaq.com - February 9 at 1:57 AM
	Actelion Ltd. breached its 50 day moving average in a Bullish Manner : January 28, 2016 (OTCMKTS:ALIOF) www.capitalcube.com - January 28 at 8:04 AM
	Alexion (ALXN) Gains after Kanuma Receives FDA Approval (OTCMKTS:ALIOF) finance.yahoo.com - December 9 at 3:35 PM